Posted 3rd September 2018 by Jane Williams
Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.
Here, Brandon talks about what he thinks the future holds for AI and machine learning:
Posted 27th July 2018 by Jane Williams
Presented at the 4th Biologics & Biosimilars Congress, these poster presentations are now available to download and share with your colleagues.
Posted 24th November 2017 by Jane Williams
Therapeutic interventions have traditionally been developed for patients with established pathologies and overt clinical symptoms. Many diseases however, are not tractable in later stages and therefore therapies are needed that intervene earlier in the disease continuum.
Posted 16th October 2017 by Jane Williams
The past decade has witnessed huge advances in both scientific research and technological innovations within the drug discovery market. Here Dr James Willans, Chief Technology Officer of the not-for-profit organisation and educational charity, Lhasa Limited, discusses two significant areas that have the potential to further transform the industry over the coming years.